Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX)
(OTCQX: LXRP) today announced the publication of final study results
of the 2018 human clinical study evaluating CBD delivery and effectiveness
using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to
the update results were published in the peer reviewed medical journal, Advances
in Therapy, which focuses on clinical medicine and pharmaceutical research
and has been published continually since 1984. Lexaria reported several key
findings highlighted in the publication, including but not limited to: CBD
in-plasma levels with the 90mg dose of TurboCBD were significantly higher than
with the generic 90 mg dose at both 90 and 120 minutes; and only the 90 mg dose
of TurboCBD was elevated (i.e., greater than the placebo) at 30 minutes and
remained elevated at 4 hours.
To view the full press releases, visit http://ibn.fm/NseX1
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in drug
delivery platforms. Its patented DehydraTECH(TM) drug delivery technology
changes the way Active Pharmaceutical Ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption; reduces time of onset; and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products; and to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed in-house research laboratory and
holds a robust intellectual property portfolio with 16 patents granted and over
60 patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and more,
these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment